Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Brise Pharmaceuticals Co. Ltd. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is being processed in 1 distinct art unit, reflecting a focused technical scope within the pharmaceutical field. The prosecution is overseen by 1 distinct examiner, ensuring a singular channel for communication and negotiation. This one-to-one ratio between the examiner and the action suggests a straightforward prosecution path.
MARTIN, KEVIN STEPHEN is the busiest examiner for this portfolio, currently handling the 1 pending office action. Because there is only a single examiner and art unit involved, the prosecution of this Biotechnology & Pharmaceuticals application is highly concentrated. This arrangement allows for a direct focus on the pending matter without the complexity of multiple examiners. The presence of 1 distinct art unit further confirms that the action addresses a specific area of biotechnology or pharmaceutical technology. Practitioners should tailor their arguments to the specific requirements of MARTIN, KEVIN STEPHEN. Maintaining a consistent dialogue with the examiner is key to resolving the 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MARTIN, KEVIN STEPHEN | 1 | 77.4% | +23.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18860882 | PIPERIDINE CARBOXAMIDE AZAINDANE DERIVATIVE, METHOD FOR PREPARING SAME, AND USE THEREOF | MARTIN, KEVIN STEPHEN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18860882 | PIPERIDINE CARBOXAMIDE AZAINDANE DERIVATIVE, METHOD FOR PREPARING SAME, AND USE THEREOF | MARTIN, KEVIN STEPHEN | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18860882 | PIPERIDINE CARBOXAMIDE AZAINDANE DERIVATIVE, METHOD FOR PREPARING SAME, AND USE THEREOF | MARTIN, KEVIN STEPHEN | 1624 | §101§112 | Non-Final OA | — | Pending | Oct 28, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBrise Pharmaceuticals Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kevin Stephen Martin has the most, with 1 of Brise Pharmaceuticals Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
